The earnings call presented strong performance in revenue growth and strategic transactions, particularly with MIPLYFFA's successful launch and European expansion efforts. However, these positives were somewhat offset by OLPRUVA's limited adoption and related financial impairments. The overall sentiment is cautiously optimistic, highlighting significant achievements with some areas of concern.

Company Guidance -

Q3 2025

During the second quarter of 2025, Zevra reported strong financial performance and strategic milestones. The company's net revenue reached $25.9 million, driven by robust demand for MIPLYFFA, which contributed $21.5 million, marking a 26% increase from the first quarter. The sale of a PRV for $150 million significantly strengthened the balance sheet. Zevra also submitted a marketing authorization application for arimoclomol in Europe, aiming to expand its geographic presence. With 129 prescription forms for MIPLYFFA, the company achieved a 1/3 market penetration among diagnosed Niemann-Pick Disease Type C patients in the U.S. The enrollment in the Phase III DiSCOVER trial for celiprolol, targeting Vascular Ehlers-Danlos syndrome, reached 39 out of 150 required patients. Despite slow adoption of OLPRUVA, Zevra's strategic focus remains on commercial excellence, pipeline advancement, and patient impact within rare diseases.

Strong Revenue Growth and Strategic Transactions

Q2 net revenue reached $25.9 million, with a 26% quarter-over-quarter increase in product net revenue for MIPLYFFA. The sale of a PRV for $150 million strengthened the balance sheet.

Successful MIPLYFFA Launch

MIPLYFFA achieved a total of 129 prescription forms by the end of Q2, covering over one-third of diagnosed Niemann-Pick Disease Type C patients in the U.S. The launch reflected robust demand and effective operational execution.

European Expansion and Regulatory Milestones

Submission of the marketing authorization application for arimoclomol in Europe marked a significant milestone, with the European market estimated to have 1,100 people living with NPC.

Financial Strength and Non-Dilutive Capital

Zevra reported $217.7 million in cash, cash equivalents, and investments, bolstered by the PRV sale, providing a strong financial position.

Zevra Therapeutics (ZVRA) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

ZVRA Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 05, 2025	2025 (Q3)	-0.03 / -	-0.69	―	―	―
Aug 12, 2025	2025 (Q2)	2.26 / 1.21	-0.48	352.08% (+1.69)	―
May 13, 2025	2025 (Q1)	-0.18 / -0.06	-0.4	85.00% (+0.34)	―
Mar 11, 2025	2024 (Q4)	-0.40 / -0.67	-0.51	-31.37% (-0.16)	―
Nov 12, 2024	2024 (Q3)	-0.41 / -0.69	-0.4	-72.50% (-0.29)
Aug 13, 2024	2024 (Q2)	-0.45 / -0.48	-0.15	-220.00% (-0.33)
May 08, 2024	2024 (Q1)	-0.47 / -0.40	-0.34	-17.65% (-0.06)	―
Mar 28, 2024	2023 (Q4)	-0.27 / -0.51	-0.26	-96.15% (-0.25)	―
Nov 07, 2023	2023 (Q3)	-0.30 / -0.40	-0.19	-110.53% (-0.21)
Aug 14, 2023	2023 (Q2)	-0.31 / -0.15	-0.7	78.57% (+0.55)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

ZVRA Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 12, 2025	$11.76	$9.43	-19.81%
May 13, 2025	$7.87	$8.14	+3.43%
Mar 11, 2025	$8.07	$7.92	-1.86%
Nov 12, 2024	$8.57	$8.66	+1.05%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Zevra Therapeutics (ZVRA) report earnings?

Zevra Therapeutics (ZVRA) is schdueled to report earning on Nov 05, 2025, TBA (Confirmed).

What is Zevra Therapeutics (ZVRA) earnings time?

Zevra Therapeutics (ZVRA) earnings time is at Nov 05, 2025, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is ZVRA EPS forecast?

ZVRA EPS forecast for the fiscal quarter 2025 (Q3) is -0.03.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing